The health clinic where Alice Okwirry collects her HIV medication in Kenya's capital Nairobi has been rationing supplies of ...

Merck (NYSE:MRK) said that data from a pair of late-stage trials showed that an oral, two-drug regimen of ...

HIV self-testing remains underutilized among not only the general public, but especially people who use drugs.

Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against ...

An annual shot to protect against HIV infection has successfully passed an early safety trial, according to research ...

Gilead has reported results for a once-yearly intramuscular injection that show blood concentrations of lenacapavir exceeded ...

ViiV Healthcare's EMBRACE study shows VH109 with CAB LA effectively suppresses HIV. The company also reports promising early ...

A new formulation of Gilead's HIV prevention drug, lenacapavir, has shown promise in providing yearlong protection with just one injection. The study, published in The Lancet, evaluated the ...

A new study led by Western researchers is the first to identify a factor that could influence how fast the pocket where human ...

Researchers from the HIV Prevention Trials Network (HPTN) have presented results from the HPTN 094 ("INTEGRA") study at the ...

Gilead Sciences set aside $200 million for a potential settlement with federal prosecutors to resolve an investigation into ...

A bill filed in Springfield would allow doctors to prescribe some HIV medication without needing prior authorization.